AbbVie Inc.
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Why AbbVie Stock Slumped Today
The company, one of the rare healthcare sector Dividend Kings, wasn't looking too royal on the last trading day of the week.
Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now
But is that performance sustainable?
The Real Price of AbbVie Stock Is Cheaper Than You Think
The sticker shock on the pharma giant's shares fades once you look at what investors are paying for the earnings expected just two years from now.
Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?
AbbVie heads into Q2 earnings with Skyrizi and Rinvoq driving growth as investors weigh Humira declines and the company's long-term outlook.
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?
Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.
Should You Buy AbbVie Stock Hand Over Fist Before July 31?
The recent rally could pave the way for "sell the news" volatility, but don't let this scare you out of a long-term position.
Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?
Both have very promising futures.
AbbVie (ABBV) Could Be 3% Undervalued Following Epcoritamab Trial Setback
Genmab and AbbVie (ABBV) recently clarified that the U.S. portion of the Phase 3 EPCORE DLBCL-1 trial for epcoritamab did not meet its overall survival primary endpoint, raising fresh questions about the drug's long term commercial potential. See our latest analysis for AbbVie. Against this backdrop, AbbVie’s share price has had a strong run, with a 30-day share price return of 10.42% and a 90-day share price return of 30.52%. Its 1-year total shareholder return of 40.53% highlights momentum...
Why Wall Street Can't Get Enough of This Dividend King
AbbVie has an attractive 2.7% yield, a solid pharmaceutical business, and is clearly focused on its dividend.
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Congressional Trades in $ABBV
Insider Trades (Form 4)
FALK THOMAS J
WADDELL FREDERICK H
Roberts Rebecca B
RAPP EDWARD J
Quaggin Susan E
MEYER MELODY B
Hart Brett J
FREYMAN THOMAS C
Key People
Davis Jennifer L
Director
WADDELL FREDERICK H
Director
Hart Brett J
Director
SALEKI-GERHARDT AZITA
EVP, CHIEF OPERATIONS OFFICER
Thakkar Roopal
EVP, R&D and CSO
Purdue David Ryan
SVP, Controller
Michael Robert A
CHAIRMAN OF THE BOARD AND CEO
Crum Demetris D
EVP, CHIEF HR OFFICER
FALK THOMAS J
Director
RAPP EDWARD J
Director
TILTON GLENN F
Director
Reents Scott T
EVP, CHIEF FINANCIAL OFFICER
Michael Robert A
CHIEF EXECUTIVE OFFICER
Buckbee Kevin K
SVP, CONTROLLER
Donoghoe Nicholas
EVP, CHIEF BUS/STRAT OFFICER
Stewart Jeffrey Ryan
EVP, CHIEF COMMERCIAL OFFICER
GONZALEZ RICHARD A
Director
Quaggin Susan E
Director
GONZALEZ RICHARD A
EXECUTIVE CHAIRMAN OF BOARD
BURNSIDE WILLIAM H L
Director
Political Giving
$360,500 given to 62 candidates across 148 disclosed contributions (FEC Schedule A).
Bradley S. Schneider
Darin McKay LaHood
Earl Leroy Carter
Adrian Smith
Nanette Barragan
Scott H. Peters
Jennifer McClellan
Terri A. Sewell
Linda T. Sanchez
Guy Mr Reschenthaler
Lori Trahan
Susan M. Collins
Ashley Moody
Thomas H. Kean
Shelley Moore Capito
James Comer
Kevin Hern
Nicole Malliotakis
Deborah Ross
David Kustoff
+ 42 more recipients not shown.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro